nach oben

Clinical Reviews in Allergy & Immunology

Erschienen in:

29.09.2016

Epigenetic Variability of CD4+CD25+ Tregs Contributes to the Pathogenesis of Autoimmune Diseases

verfasst von: Ye Shu, Qinghua Hu, Hai Long, Christopher Chang, Qianjin Lu, Rong Xiao

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Autoimmune diseases are characterized by aberrant immune responses against healthy cells and tissues. However, the exact mechanisms underlying the development of these conditions remain unknown. CD4+CD25+ regulatory T cells (Tregs) are a subset of mature T cells which have an important role in maintaining immune homeostasis and preventing autoimmune diseases. Forkhead box p3 (Foxp3), a member of the fork head transcription factor family, is recognized as a marker of CD4+CD25+ Tregs. The decreased number and/or function of CD4+CD25+ Tregs in peripheral blood and related tissues has been demonstrated in systemic lupus erythematosus, systemic sclerosis, and other autoimmune diseases, which are at least partially regulated by epigenetic mechanisms. Epigenetics refers to the study of potentially heritable alterations in gene expression without underlying changes of the nucleotide sequence, mainly including DNA methylation, histone modification, and microRNAs (miRNAs). For example, DNA methylation status of CpG islands on the Foxp3 gene, which may be affected by normal aging and regulated by environmental factors, plays an important role in modulating the homeostasis of Foxp3 expression in Tregs. Foxp3 gene in Tregs also shows distinct acetylation and trimethylation levels of histone H3 and H4 when compared with effector T cells, leading to an open chromatin structure. MicroRNAs such as miR-155, miR-126, and miR-10a also exert an important influence on the differentiation, development, and immunological functions of Tregs. Aberrant epigenetic modifications affecting Foxp3 and other key genes in Tregs contribute to disease activity and tissue inflammation in autoimmune diseases, which holds great potential for providing novel targets for epigenetic therapies. Advances in research into the epigenetic regulation of CD4+CD25+ Tregs may also lead to the identification of new epigenetic biomarkers for diagnosis and prognosis.

Walker MR, Kasprowicz DJ, Gersuk VH, Benard A, Van Landeghen M, Buckner JH, Ziegler SF (2003) Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25− T cells. J Clin Invest 112:1437–1443CrossRefPubMed

Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F (2001) Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 27:68–73CrossRefPubMed

Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N, Levy-Lahad E, Mazzella M, Goulet O, Perroni L, Bricarelli FD, Byrne G, McEuen M, Proll S, Appleby M, Brunkow ME (2001) X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 27:18–20CrossRefPubMed

Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD (2001) The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27:20–21CrossRefPubMed

Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA (2004) Natural and induced CD4+CD25+ cells educate CD4+CD25− cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. J Immunol 172:5213–5221CrossRefPubMed

Pedros C, Gaud G, Bernard I, Kassem S, Chabod M, Lagrange D, Andreoletti O, Dejean AS, Lesourne R, Fournie GJ, Saoudi A (2015) An epistatic interaction between Themis1 and Vav1 modulates regulatory T cell function and inflammatory bowel disease development. J Immunol 195:1608–1616CrossRefPubMed

Barron L, Dooms H, Hoyer KK, Kuswanto W, Hofmann J, O’Gorman WE, Abbas AK (2010) Cutting edge: mechanisms of IL-2-dependent maintenance of functional regulatory T cells. J Immunol 185:6426–6430CrossRefPubMedPubMedCentral

Lio CW, Hsieh CS (2008) A two-step process for thymic regulatory T cell development. Immunity 28:100–111CrossRefPubMedPubMedCentral

Lu Y, Wang J, Gu J, Lu H, Li X, Qian X, Liu X, Wang X, Zhang F, Lu L (2014) Rapamycin regulates iTreg function through CD39 and Runx1 pathways. J Immunol Res 2014:989434PubMedPubMedCentral

10.

Guereschi MG, Araujo LP, Maricato JT, Takenaka MC, Nascimento VM, Vivanco BC, Reis VO, Keller AC, Brum PC, Basso AS (2013) Beta2-adrenergic receptor signaling in CD4+ Foxp3+ regulatory T cells enhances their suppressive function in a PKA-dependent manner. Eur J Immunol 43:1001–1012CrossRefPubMed

11.

Zhang B, Dou Y, Xu X, Wang X, Xu B, Du J, Wang Q, Li Q, Wang J (2015) Endogenous FOXP3 inhibits cell proliferation, migration and invasion in glioma cells. Int J Clin Exp Med 8:1792–1802PubMedPubMedCentral

12.

Ma GF, Chen SY, Sun ZR, Miao Q, Liu YM, Zeng XQ, Luo TC, Ma LL, Lian JJ, Song DL (2013) FoxP3 inhibits proliferation and induces apoptosis of gastric cancer cells by activating the apoptotic signaling pathway. Biochem Biophys Res Commun 430:804–809CrossRefPubMed

13.

Toker A, Huehn J (2011) To be or not to be a Treg cell: lineage decisions controlled by epigenetic mechanisms. Sci Signal 4:pe4CrossRefPubMed

14.

Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J, Schlawe K, Chang HD, Bopp T, Schmitt E, Klein-Hessling S, Serfling E, Hamann A, Huehn J (2007) Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 5:e38CrossRefPubMedPubMedCentral

15.

Baron U, Floess S, Wieczorek G, Baumann K, Grutzkau A, Dong J, Thiel A, Boeld TJ, Hoffmann P, Edinger M, Turbachova I, Hamann A, Olek S, Huehn J (2007) DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol 37:2378–2389CrossRefPubMed

16.

Kim HP, Leonard WJ (2007) CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation. J Exp Med 204:1543–1551CrossRefPubMedPubMedCentral

17.

Zheng Y, Josefowicz S, Chaudhry A, Peng XP, Forbush K, Rudensky AY (2010) Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 463:808–812CrossRefPubMedPubMedCentral

18.

Lal G, Zhang N, van der Touw W, Ding Y, Ju W, Bottinger EP, Reid SP, Levy DE, Bromberg JS (2009) Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol 182:259–273CrossRefPubMedPubMedCentral

19.

Garg SK, Delaney C, Toubai T, Ghosh A, Reddy P, Banerjee R, Yung R (2014) Aging is associated with increased regulatory T-cell function. Aging Cell 13:441–448CrossRefPubMedPubMedCentral

20.

Nadeau K, McDonald-Hyman C, Noth EM, Pratt B, Hammond SK, Balmes J, Tager I (2010) Ambient air pollution impairs regulatory T-cell function in asthma. J Allergy Clin Immunol 126(845–852):e810

21.

Brunst KJ, Leung YK, Ryan PH, Khurana Hershey GK, Levin L, Ji H, Lemasters GK, Ho SM (2013) Forkhead box protein 3 (FOXP3) hypermethylation is associated with diesel exhaust exposure and risk for childhood asthma. J Allergy Clin Immunol 131(592–594):e591–e593

22.

Ngalamika O, Liang G, Zhao M, Yu X, Yang Y, Yin H, Liu Y, Yung S, Chan TM, Lu Q (2015) Peripheral whole blood FOXP3 TSDR methylation: a potential marker in severity assessment of autoimmune diseases and chronic infections. Immunol Invest 44:126–136CrossRefPubMed

23.

Wiencke JK, Accomando WP, Zheng S, Patoka J, Dou X, Phillips JJ, Hsuang G, Christensen BC, Houseman EA, Koestler DC, Bracci P, Wiemels JL, Wrensch M, Nelson HH, Kelsey KT (2012) Epigenetic biomarkers of T-cells in human glioma. Epigenetics 7:1391–1402CrossRefPubMedPubMedCentral

24.

Syed A, Garcia MA, Lyu SC, Bucayu R, Kohli A, Ishida S, Berglund JP, Tsai M, Maecker H, O’Riordan G, Galli SJ, Nadeau KC (2014) Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol 133:500–510CrossRefPubMedPubMedCentral

25.

Swamy RS, Reshamwala N, Hunter T, Vissamsetti S, Santos CB, Baroody FM, Hwang PH, Hoyte EG, Garcia MA, Nadeau KC (2012) Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy. J Allergy Clin Immunol 130(215–224):e217

26.

Singer BD, Mock JR, Aggarwal NR, Garibaldi BT, Sidhaye VK, Florez MA, Chau E, Gibbs KW, Mandke P, Tripathi A, Yegnasubramanian S, King LS, D’Alessio FR (2015) Regulatory T cell DNA methyltransferase inhibition accelerates resolution of lung inflammation. Am J Respir Cell Mol Biol 52:641–652CrossRefPubMedPubMedCentral

27.

Mangano K, Fagone P, Bendtzen K, Meroni PL, Quattrocchi C, Mammana S, Di Rosa M, Malaguarnera L, Coco M, Magro G, Di Marco R, Nicoletti F (2014) Hypomethylating agent 5-aza-2′-deoxycytidine (DAC) ameliorates multiple sclerosis in mouse models. J Cell Physiol 229:1918–1925CrossRefPubMed

28.

Lu L, Lan Q, Li Z, Zhou X, Gu J, Li Q, Wang J, Chen M, Liu Y, Shen Y, Brand DD, Ryffel B, Horwitz DA, Quismorio FP, Liu Z, Li B, Olsen NJ, Zheng SG (2014) Critical role of all-trans retinoic acid in stabilizing human natural regulatory T cells under inflammatory conditions. Proc Natl Acad Sci U S A 111:E3432–E3440CrossRefPubMedPubMedCentral

29.

Obata Y, Furusawa Y, Endo TA, Sharif J, Takahashi D, Atarashi K, Nakayama M, Onawa S, Fujimura Y, Takahashi M, Ikawa T, Otsubo T, Kawamura YI, Dohi T, Tajima S, Masumoto H, Ohara O, Honda K, Hori S, Ohno H, Koseki H, Hase K (2014) The epigenetic regulator Uhrf1 facilitates the proliferation and maturation of colonic regulatory T cells. Nat Immunol 15:571–579CrossRefPubMed

30.

Xiong Y, Khanna S, Grzenda AL, Sarmento OF, Svingen PA, Lomberk GA, Urrutia RA, Faubion WA Jr (2012) Polycomb antagonizes p300/CREB-binding protein-associated factor to silence FOXP3 in a Kruppel-like factor-dependent manner. J Biol Chem 287:34372–34385CrossRefPubMedPubMedCentral

31.

Xiong Y, Svingen PA, Sarmento OO, Smyrk TC, Dave M, Khanna S, Lomberk GA, Urrutia RA, Faubion WA Jr (2014) Differential coupling of KLF10 to Sin3-HDAC and PCAF regulates the inducibility of the FOXP3 gene. Am J Physiol Regul Integr Comp Physiol 307:R608–R620CrossRefPubMedPubMedCentral

32.

Sarmento OF, Svingen PA, Xiong Y, Xavier RJ, McGovern D, Smyrk TC, Papadakis KA, Urrutia RA, Faubion WA (2015) A novel role for KLF14 in T regulatory cell differentiation. Cell Mol Gastroenterol Hepatol 1(188–202):e184

33.

Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM, Li B, Turka LA, Olson EN, Greene MI, Wells AD, Hancock WW (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 13:1299–1307CrossRefPubMed

34.

Liesz A, Zhou W, Na SY, Hammerling GJ, Garbi N, Karcher S, Mracsko E, Backs J, Rivest S, Veltkamp R (2013) Boosting regulatory T cells limits neuroinflammation in permanent cortical stroke. J Neurosci 33:17350–17362CrossRefPubMed

35.

Li Q, Zou J, Wang M, Ding X, Chepelev I, Zhou X, Zhao W, Wei G, Cui J, Zhao K, Wang HY, Wang RF (2014) Critical role of histone demethylase Jmjd3 in the regulation of CD4+ T-cell differentiation. Nat Commun 5:5780CrossRefPubMedPubMedCentral

36.

Kohlhaas S, Garden OA, Scudamore C, Turner M, Okkenhaug K, Vigorito E (2009) Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells. J Immunol 182:2578–2582CrossRefPubMed

37.

Lu LF, Thai TH, Calado DP, Chaudhry A, Kubo M, Tanaka K, Loeb GB, Lee H, Yoshimura A, Rajewsky K, Rudensky AY (2009) Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 30:80–91CrossRefPubMedPubMedCentral

38.

Qin A, Wen Z, Zhou Y, Li Y, Li Y, Luo J, Ren T, Xu L (2013) MicroRNA-126 regulates the induction and function of CD4(+) Foxp3(+) regulatory T cells through PI3K/AKT pathway. J Cell Mol Med 17:252–264CrossRefPubMedPubMedCentral

39.

Jeker LT, Zhou X, Gershberg K, de Kouchkovsky D, Morar MM, Stadthagen G, Lund AH, Bluestone JA (2012) MicroRNA 10a marks regulatory T cells. PLoS One 7:e36684CrossRefPubMedPubMedCentral

40.

Cai XY, Luo M, Lin XJ, Xu YL, Tang C, Ye JH, Li WN, He ZX, Yu N (2012) Expression and significance of Th17 and Treg cells in peripheral blood of patients with systemic lupus erythematosus. Zhonghua Yi Xue Za Zhi 92:460–463PubMed

41.

Tselios K, Sarantopoulos A, Gkougkourelas I, Boura P (2014) CD4+CD25highFOXP3+ T regulatory cells as a biomarker of disease activity in systemic lupus erythematosus: a prospective study. Clin Exp Rheumatol 32:630–639PubMed

42.

Xing Q, Wang B, Su H, Cui J, Li J (2012) Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis. Rheumatol Int 32:949–958CrossRefPubMed

43.

Lin XJ, Luo M, Cai XY (2011) Study of fas-mediated Foxp3+CD4+CD25+ Treg cell apoptosis in patients with systemic lupus erythematosus. Zhonghua Yi Xue Za Zhi 91:586–590PubMed

44.

Ma J, Yu J, Tao X, Cai L, Wang J, Zheng SG (2010) The imbalance between regulatory and IL-17-secreting CD4+ T cells in lupus patients. Clin Rheumatol 29:1251–1258CrossRefPubMed

45.

Yu L, Huang A, Wang W, Du R, Shen L, Hou X (2011) Relatively increased number of liver Foxp(3+) regulatory T cells against hepatic lesions in murine lupus. J Huazhong Univ Sci Technolog Med Sci 31:476–481CrossRefPubMed

46.

Weigert O, von Spee C, Undeutsch R, Kloke L, Humrich JY, Riemekasten G (2013) CD4+Foxp3+ regulatory T cells prolong drug-induced disease remission in (NZBxNZW) F1 lupus mice. Arthritis Res Ther 15:R35CrossRefPubMedPubMedCentral

47.

Zhao M, Liang GP, Tang MN, Luo SY, Zhang J, Cheng WJ, Chan TM, Lu QJ (2012) Total glucosides of paeony induces regulatory CD4(+)CD25(+) T cells by increasing Foxp3 demethylation in lupus CD4(+) T cells. Clin Immunol 143:180–187CrossRefPubMed

48.

Absher DM, Li X, Waite LL, Gibson A, Roberts K, Edberg J, Chatham WW, Kimberly RP (2013) Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell populations. PLoS Genet 9:e1003678CrossRefPubMedPubMedCentral

49.

Regna NL, Chafin CB, Hammond SE, Puthiyaveetil AG, Caudell DL, Reilly CM (2014) Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo. Clin Immunol 151:29–42CrossRefPubMedPubMedCentral

50.

Tselios K, Sarantopoulos A, Gkougkourelas I, Papagianni A, Boura P (2014) Increase of peripheral T regulatory cells during remission induction with cyclophosphamide in active systemic lupus erythematosus. Int J Rheum Dis 17:790–795CrossRefPubMed

51.

Tselios K, Sarantopoulos A, Gkougkourelas I, Boura P (2015) The influence of therapy on CD4+CD25(high)FOXP3+ regulatory T cells in systemic lupus erythematosus patients: a prospective study. Scand J Rheumatol 44:29–35CrossRefPubMed

52.

Qiao G, Yang L, Li Z, Williams JW, Zhang J (2015) A77 1726, the active metabolite of leflunomide, attenuates lupus nephritis by promoting the development of regulatory T cells and inhibiting IL-17-producing double negative T cells. Clin Immunol 157:166–174CrossRefPubMed

53.

Koga T, Mizui M, Yoshida N, Otomo K, Lieberman LA, Crispin JC, Tsokos GC (2014) KN-93, an inhibitor of calcium/calmodulin-dependent protein kinase IV, promotes generation and function of Foxp3(+) regulatory T cells in MRL/lpr mice. Autoimmunity 47:445–450CrossRefPubMedPubMedCentral

54.

Klein S, Kretz CC, Ruland V, Stumpf C, Haust M, Hartschuh W, Hartmann M, Enk A, Suri-Payer E, Oberle N, Krammer PH, Kuhn A (2011) Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic scleroderma. Ann Rheum Dis 70:1475–1481CrossRefPubMed

55.

Antiga E, Quaglino P, Bellandi S, Volpi W, Del Bianco E, Comessatti A, Osella-Abate S, De Simone C, Marzano A, Bernengo MG, Fabbri P, Caproni M (2010) Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. Br J Dermatol 162:1056–1063CrossRefPubMed

56.

Kataoka H, Yasuda S, Fukaya S, Oku K, Horita T, Atsumi T, Koike T (2015) Decreased expression of Runx1 and lowered proportion of Foxp3(+) CD25(+) CD4(+) regulatory T cells in systemic sclerosis. Mod Rheumatol 25:90–95CrossRefPubMed

57.

Mathian A, Parizot C, Dorgham K, Trad S, Arnaud L, Larsen M, Miyara M, Hie M, Piette JC, Frances C, Yssel H, Amoura Z, Gorochov G (2012) Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. Ann Rheum Dis 71:1227–1234CrossRefPubMed

58.

Baraut J, Grigore EI, Jean-Louis F, Khelifa SH, Durand C, Verrecchia F, Farge D, Michel L (2014) Peripheral blood regulatory T cells in patients with diffuse systemic sclerosis (SSc) before and after autologous hematopoietic SCT: a pilot study. Bone Marrow Transplant 49:349–354CrossRefPubMed

59.

Quaglino P, Ponti R, Novelli M, Savoia P, Fava P, Papini M, Bernengo MG (2013) Flow cytometric analyses of circulating regulatory T cells in patients with dermatitis herpetiformis and other immune mediated dermatoses. G Ital Dermatol Venereol 148:197–201PubMed

60.

Wang YY, Wang Q, Sun XH, Liu RZ, Shu Y, Kanekura T, Huang JH, Li YP, Wang JC, Zhao M, Lu QJ, Xiao R (2014) DNA hypermethylation of the forkhead box protein 3 (FOXP3) promoter in CD4+ T cells of patients with systemic sclerosis. Br J Dermatol 171:39–47CrossRefPubMed

61.

Niu Q, Cai B, Huang ZC, Shi YY, Wang LL (2012) Disturbed Th17/Treg balance in patients with rheumatoid arthritis. Rheumatol Int 32:2731–2736CrossRefPubMed

62.

Kawashiri SY, Kawakami A, Okada A, Koga T, Tamai M, Yamasaki S, Nakamura H, Origuchi T, Ida H, Eguchi K (2011) CD4+CD25(high)CD127(low/−) Treg cell frequency from peripheral blood correlates with disease activity in patients with rheumatoid arthritis. J Rheumatol 38:2517–2521CrossRefPubMed

63.

Kennedy A, Schmidt EM, Cribbs AP, Penn H, Amjadi P, Syed K, Read JE, Green P, Gregory B, Brennan FM (2014) A novel upstream enhancer of FOXP3, sensitive to methylation-induced silencing, exhibits dysregulated methylation in rheumatoid arthritis Treg cells. Eur J Immunol 44:2968–2978CrossRefPubMed

64.

Cribbs AP, Kennedy A, Penn H, Amjadi P, Green P, Read JE, Brennan F, Gregory B, Williams RO (2015) Methotrexate restores regulatory T cell function through demethylation of the FoxP3 upstream enhancer in patients with rheumatoid arthritis. Arthritis Rheumatol 67:1182–1192CrossRefPubMed

65.

Lin F, Luo X, Tsun A, Li Z, Li D, Li B (2015) Kaempferol enhances the suppressive function of Treg cells by inhibiting FOXP3 phosphorylation. Int Immunopharmacol 28:859–865CrossRefPubMed

66.

Rossetti M, Spreafico R, Saidin S, Chua C, Moshref M, Leong JY, Tan YK, Thumboo J, van Loosdregt J, Albani S (2015) Ex vivo-expanded but not in vitro-induced human regulatory T cells are candidates for cell therapy in autoimmune diseases thanks to stable demethylation of the FOXP3 regulatory T cell-specific demethylated region. J Immunol 194:113–124CrossRefPubMed

67.

Dong L, Wang X, Tan J, Li H, Qian W, Chen J, Chen Q, Wang J, Xu W, Tao C, Wang S (2014) Decreased expression of microRNA-21 correlates with the imbalance of Th17 and Treg cells in patients with rheumatoid arthritis. J Cell Mol Med 18:2213–2224CrossRefPubMedPubMedCentral

68.

Zhou Q, Haupt S, Kreuzer JT, Hammitzsch A, Proft F, Neumann C, Leipe J, Witt M, Schulze-Koops H, Skapenko A (2015) Decreased expression of miR-146a and miR-155 contributes to an abnormal Treg phenotype in patients with rheumatoid arthritis. Ann Rheum Dis 74:1265–1274CrossRefPubMed

69.

Su D, Shen M, Gu B, Wang X, Wang D, Li X, Sun L (2014) Tc-methylene diphosphonate improves rheumatoid arthritis disease activity by increasing the frequency of peripheral gammadelta T cells and CD4 CD25 Foxp3 Tregs. Int J Rheum Dis 19(6):586–593CrossRefPubMed

70.

Moon SJ, Lim MA, Park JS, Byun JK, Kim SM, Park MK, Kim EK, Moon YM, Min JK, Ahn SM, Park SH, Cho ML (2014) Dual-specificity phosphatase 5 attenuates autoimmune arthritis in mice via reciprocal regulation of the Th17/Treg cell balance and inhibition of osteoclastogenesis. Arthritis Rheumatol 66:3083–3095CrossRefPubMed

71.

Moon SJ, Park JS, Woo YJ, Lim MA, Kim SM, Lee SY, Kim EK, Lee HJ, Lee WS, Park SH, Jeong JH, Park SH, Kim HY, Cho ML, Min JK (2014) Rebamipide suppresses collagen-induced arthritis through reciprocal regulation of th17/treg cell differentiation and heme oxygenase 1 induction. Arthritis Rheumatol 66:874–885CrossRefPubMed

72.

Byun JK, Moon SJ, Jhun JY, Kim EK, Park JS, Youn J, Min JK, Park SH, Kim HY, Cho ML (2014) Rebamipide attenuates autoimmune arthritis severity in SKG mice via regulation of B cell and antibody production. Clin Exp Immunol 178:9–19CrossRefPubMedPubMedCentral

73.

Ahmad SF, Zoheir KM, Bakheet SA, Ashour AE, Attia SM (2014) Poly(ADP-ribose) polymerase-1 inhibitor modulates T regulatory and IL-17 cells in the prevention of adjuvant induced arthritis in mice model. Cytokine 68:76–85CrossRefPubMed

74.

Richetta AG, Mattozzi C, Salvi M, Giancristoforo S, D’Epiro S, Milana B, Carboni V, Zampetti M, Calvieri S, Morrone S (2011) CD4+ CD25+ T-regulatory cells in psoriasis. Correlation between their numbers and biologics-induced clinical improvement. Eur J Dermatol 21:344–348PubMed

75.

Zhao M, Wang LT, Liang GP, Zhang P, Deng XJ, Tang Q, Zhai HY, Chang CC, Su YW, Lu QJ (2014) Up-regulation of microRNA-210 induces immune dysfunction via targeting FOXP3 in CD4(+) T cells of psoriasis vulgaris. Clin Immunol 150:22–30CrossRefPubMed

76.

Bovenschen HJ, van de Kerkhof PC, van Erp PE, Woestenenk R, Joosten I, Koenen HJ (2011) Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol 131:1853–1860CrossRefPubMed

77.

El-Darouti MA, Hegazy RA, Abdel Hay RM, Rashed LA (2014) Study of T helper (17) and T regulatory cells in psoriatic patients receiving live attenuated varicella vaccine therapy in a randomized controlled trial. Eur J Dermatol 24:464–469PubMed

78.

Quaglino P, Bergallo M, Ponti R, Barberio E, Cicchelli S, Buffa E, Comessatti A, Costa C, Terlizzi ME, Astegiano S, Novelli M, Cavallo R, Bernengo MG (2011) Th1, Th2, Th17 and regulatory T cell pattern in psoriatic patients: modulation of cytokines and gene targets induced by etanercept treatment and correlation with clinical response. Dermatology 223:57–67CrossRefPubMed

79.

Furuhashi T, Saito C, Torii K, Nishida E, Yamazaki S, Morita A (2013) Photo(chemo)therapy reduces circulating Th17 cells and restores circulating regulatory T cells in psoriasis. PLoS One 8:e54895CrossRefPubMedPubMedCentral

80.

Singh TP, Schon MP, Wallbrecht K, Michaelis K, Rinner B, Mayer G, Schmidbauer U, Strohmaier H, Wang XJ, Wolf P (2010) 8-Methoxypsoralen plus ultraviolet A therapy acts via inhibition of the IL-23/Th17 axis and induction of Foxp3+ regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder. J Immunol 184:7257–7267CrossRefPubMed

81.

Ferraro A, Socci C, Stabilini A, Valle A, Monti P, Piemonti L, Nano R, Olek S, Maffi P, Scavini M, Secchi A, Staudacher C, Bonifacio E, Battaglia M (2011) Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 60:2903–2913CrossRefPubMedPubMedCentral

82.

Wang Z, Zheng Y, Hou C, Yang L, Li X, Lin J, Huang G, Lu Q, Wang CY, Zhou Z (2013) DNA methylation impairs TLR9 induced Foxp3 expression by attenuating IRF-7 binding activity in fulminant type 1 diabetes. J Autoimmun 41:50–59CrossRefPubMed

83.

Hezova R, Slaby O, Faltejskova P, Mikulkova Z, Buresova I, Raja KR, Hodek J, Ovesna J, Michalek J (2010) microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cell Immunol 260:70–74CrossRefPubMed

84.

Mohammadnia-Afrouzi M, Hosseini AZ, Khalili A, Abediankenari S, Amari A, Aghili B, Nataj HH (2016) Altered microRNA expression and immunosuppressive cytokine production by regulatory T cells of ulcerative colitis patients. Immunol Invest 45:63–74CrossRefPubMed

85.

Singh Y, Garden OA, Lang F, Cobb BS (2015) MicroRNA-15b/16 enhances the induction of regulatory T cells by regulating the expression of Rictor and mTOR. J Immunol 195:5667–5677CrossRefPubMedPubMedCentral

86.

De Santis G, Ferracin M, Biondani A, Caniatti L, Rosaria Tola M, Castellazzi M, Zagatti B, Battistini L, Borsellino G, Fainardi E, Gavioli R, Negrini M, Furlan R, Granieri E (2010) Altered miRNA expression in T regulatory cells in course of multiple sclerosis. J Neuroimmunol 226:165–171CrossRefPubMed

87.

Zhang R, Tian A, Wang J, Shen X, Qi G, Tang Y (2015) miR26a modulates Th17/Treg balance in the EAE model of multiple sclerosis by targeting IL6. Neuromolecular Med 17:24–34CrossRefPubMed

88.

de Kouchkovsky D, Esensten JH, Rosenthal WL, Morar MM, Bluestone JA, Jeker LT (2013) microRNA-17-92 regulates IL-10 production by regulatory T cells and control of experimental autoimmune encephalomyelitis. J Immunol 191:1594–1605CrossRefPubMedPubMedCentral

Titel: Epigenetic Variability of CD4+CD25+ Tregs Contributes to the Pathogenesis of Autoimmune Diseases
verfasst von: Ye Shu
Qinghua Hu
Hai Long
Christopher Chang
Qianjin Lu
Rong Xiao
Publikationsdatum: 29.09.2016
Verlag: Springer US
Erschienen in: Clinical Reviews in Allergy & Immunology / Ausgabe 2/2017
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-016-8590-3

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Epigenetic Variability of CD4+CD25+ Tregs Contributes to the Pathogenesis of Autoimmune Diseases

Abstract

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Beyond Genetics: What Causes Type 1 Diabetes

An Update on the Use of Immunomodulators in Primary Immunodeficiencies

Review of Mouse Models of Graves’ Disease and Orbitopathy—Novel Treatment by Induction of Tolerance

Adipose-Derived Mesenchymal Stem Cells in Autoimmune Disorders: State of the Art and Perspectives for Systemic Sclerosis

The Clinical Relevance of Anti-DFS70 Autoantibodies

CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO